

World Leading Innate Immunity Specialists to Convene for Roundtable Discussion:

"Innate immunity: from revolutionary discovery to revolution in therapy" - May 15, 2012, in Paris at 10:30 am

- **Panel of internationally renowned speakers** including Nobel Prize winners in Medicine 2011 and Philippe Kourilsky, professor at the Collège de France, as moderator;
- **Dedicated website** www.immunite-innee.com to submit questions that will feed the debate and to watch the roundtable broadcast on the following Monday.


Paris and Marseille, April 16, 2012: [Bristol-Myers Squibb France](#) and [Innate Pharma](#) to host a roundtable event including internationally renowned panel speakers to discuss the topic **"Innate immunity: from revolutionary discovery to revolution in therapy."** Special guests, **Bruce Beutler** and **Jules Hoffman**, the 2011 Nobel Prize winners in Medicine, will join the debate which will take place on May 15, 2012 at the Oceanographic Institute of Paris, France.

Immunotherapy, especially in cancer research, is a topical issue and source of debate amongst the medical community. This roundtable will give an insight yet unexplored into the innate compartment of the immune system.

Participation in this roundtable is by invitation only. A dedicated website is now live (www.immunite-innee.com) so visitors can access detailed information on the event and submit questions directly to the roundtable moderator Philippe Kourilsky prior to the debate on May 15 which will fuel discussions. A video replay will be available online shortly after the event. Discussions will be conducted in English.

All aspects of innate immunity - from the fundamentals to clinical trials - will be covered by our expert speakers:

- **Two 2011 Nobel prize winners in medicine, Dr. Jules Hoffmann** from the Institute of Molecular and Cellular Biology at the University of Strasbourg, and **Dr. Bruce Beutler** of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical School, whose scientific discoveries have contributed to the elucidation of mechanisms of activation of the innate immune system;
- **Pr. Jean-Yves Blay**, Professor of Medical Oncology, Centre Leon Berard in Lyon, chairing the European organization for the research of cancer treatments (EORTC), who has developed a wealth of experience in cancer immunotherapy;
- **Dr. Nils Lonberg**, Senior Vice President in charge of research and development of biological drugs, Bristol-Myers Squibb, who participated in the development of the first antibody modulator of T cells;
- **Pr. Eric Vivier**, Director, Center for Immunology Marseille-Luminy, who is a co-founder of Innate Pharma and a specialist of natural killer cells.



Pr. Philippe Kourilsky, Chair of Immunology at the Collège de France and former Director of the Pasteur Institute, will moderate the discussion.

This roundtable is organized by Bristol-Myers Squibb France and Innate Pharma:

Bristol-Myers Squibb is a biopharmaceutical company with renowned expertise in immunology. It has developed and made available to patients a treatment for rheumatoid arthritis, the first immunotherapy for metastatic melanoma, as well as a treatment for the prevention of renal transplant rejection. Phase III clinical trials are also ongoing for two immunotherapeutics in lung, prostate and kidney cancer.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. Its drug candidates belong to a new class of therapeutic agents and consist of monoclonal antibodies aimed at immune regulatory checkpoints with a unique focus on the innate immunity compartment. This innovative approach has been validated by two major biopharmaceutical partners: Bristol-Myers Squibb in cancer and Novo Nordisk A/S in inflammation.

Bristol Myers Squibb and Innate Pharma have been collaborating in the field of innate immunomodulation since July 2011 through the IPH21 programme. Developed by Innate Pharma and licensed by Bristol Myers Squibb, IPH2102 is currently in Phase I clinical trials and is the first immunotherapy specifically targeting innate immunity cells – Natural Killer Cells - with the aim of harnessing them to fight against cancer.

Hervé Brailly, CEO of Innate Pharma, said: *"In this unique roundtable, Innate Pharma and Bristol-Myers Squibb wish to further highlight the important therapeutic potential of innate immunity and celebrate a field of science that was awarded the prestigious Nobel Prize in Medicine in 2011. We very much hope that the roundtable will broaden our understanding of this cutting-edge field and foster debate amongst our peers, our stakeholders and the medical community to help further understand the possibilities of developing highly innovative products that modulate innate immunity."*

Mike Seeley, President of Bristol-Myers Squibb France, said: *"Bristol-Myers Squibb is a global leader in the field of immunotherapy but it is only recently that it approached the modulation of innate immunity, through the collaboration with Innate Pharma on the "anti-KIR" IPH21 programme. This partnership is also reflected through our desire to instigate such meetings that we hope are productive in terms of exchanges between academics, cancer specialists and the industry."*

About the speakers:

MODERATOR: PHILIPPE KOURILSKY

A biologist from the Ecole Polytechnique, Philippe Kourilsky has been the Chair of Immunology at the College de France and member of the Academy of Sciences since 1998. He has also chaired the Singapore Immunology Network (SIgN) focusing on human immunology since its inception in 2006.

Philippe Kourilsky is a member of the Board of Directors of Veolia Environnement, where he chairs the committee on Strategic Research Innovation and Sustainable Development.

BRUCE BEUTLER

An American geneticist specializing in immunology, Bruce Beutler won the 2011 Nobel Prize for Medicine for his discoveries in the field of activation of the innate immune system.

Having worked at the Rockefeller University in New York and at the University of Texas Southwestern Medical School at Dallas, he joined, in 2000, the Scripps Research Institute in La Jolla, California, where he taught genetics and immunology and was head of the genetics department. He is now an adjunct professor at that institute. Bruce Beutler currently heads the Center for the Genetics of Host Defense, University of Texas Southwestern Medical School at Dallas.

JEAN-YVES BLAY

Professor of Medical Oncology at the University of Lyon, Jean-Yves Blay is Head of the Oncology Translational research center at the Centre for the Fight Against Cancer (CLCC) Leon Berard in Lyon.

Jean-Yves Blay is also President of the European Organization for Research and Treatment of Cancer (EORTC) and the Site Director of Integrated Research on Cancer in Lyon (SIRIC), one of the two French sites for integrated multidisciplinary research accredited by the Institute national du Cancer (INCA).


JULES HOFFMANN

A French biologist from Luxembourg, Jules Hoffmann was awarded the 2011 Nobel Prize for Medicine for his work on the immune system. In the 70s he established the laboratory "Immune response and development in insects" at the Institute of Molecular and Cellular Biology of the CNRS in Strasbourg, where he was director from 1994 to 2006. Research Director at the CNRS, Jules Hoffmann was awarded the gold medal of the CNRS.

A member of the Academy of Sciences (which he chaired in 2007 and 2008), Jules Hoffmann was elected to the Académie française in 2012.

NILS LONBERG

Vice President in charge of research and development of biological drugs from Bristol-Myers Squibb, Nils Lonberg was previously with Medarex and GenPharm International. His laboratory developed and exploited a transgenic mouse platform behind the first fully human antibodies. More than two dozen drugs from this platform have entered clinical development, five of which are marketed today.



ÉRIC VIVIER

Professor of Immunology at the Medical Faculty of Marseille and Hospital Practitioner, Eric Vivier is Director of the Centre of Immunology of Marseille-Luminy, where his team studies the cell biology of "Natural Killer" cells. Eric Vivier is a member of the Institut Universitaire de France, member of the scientific committee of the LNCC (French National League against Cancer), scientific advisor for the Institute of Hematology-Immunology-Pulmonology (INSERM) and member of the expert committee for the European Research Council (ERC) Starting Grant. He is one of the scientific founders of Innate Pharma.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose goal is to discover, develop and deliver innovative drugs that help patients prevail over serious diseases. For more information, please visit www.bmsfrance.fr or follow us on Twitter at <http://twitter.com/#!/bmsnews>.

About Innate Pharma

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. The mechanisms controlling these cells were described at the end of the 90s, notably by the teams of the scientists who founded Innate Pharma. This innovating approach has been validated by two major biopharmaceutical partners: Bristol-Myers Squibb in cancer and Novo Nordisk A/S in inflammation. Learn more about Innate Pharma at www.innate-pharma.com.

Contacts

ATCG Press

Marielle Bricman
Director

Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com

Innate Pharma

Laure-Hélène Mercier
Director, Investor Relations

Phone: +33 (0)4 30 30 30 87
Laure-Helene.Mercier@innate-pharma.fr

Bristol-Myers Squibb France

Catherine Liabeuf
Associated Director Public
Affairs

Phone: +33 (0)1 58 83 87 92
catherine.liabeuf@bms.com